Compound Detail
CHEMBL4596392
CRAVACITINIB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL4596392 |
| Name | CRAVACITINIB |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | BZZKEPGENYLQSC-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
2
Targets
12
Activities
2
Assay Types
0
PK Parameters
1
Publications
1
Known Names
Molecular Properties
422.4
MW (Da)
1.73
ALogP
9
HBA
3
HBD
135.9
PSA (Ų)
0.52
QED
0
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2022 |
| Availability | Prescription |
| Chirality | Achiral |
Activity Summary
IC50 10 meas. best 8.26
EC50 2 meas. best 8.29
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Non-receptor tyrosine-protein kinase TYK2 CHEMBL3553 | EC50 | 8.29 | 8.24 | 5.1 | 2 |
| Non-receptor tyrosine-protein kinase TYK2 CHEMBL3553 | IC50 | 8.26 | 7.194 | 5.5 | 5 |
| Tyrosine-protein kinase JAK2 CHEMBL2971 | IC50 | 6.08 | 5.708 | 840.0 | 5 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 2 |
Data from ChEMBL 36 via Core Engine